Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3025-3032

  Pannier, Anne ^a   Jordan, Paul ^a   Dougherty, Frank C ^a   Bour, Fabrice ^b   Reigner, Bruno ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Roche   (France)

Author keywords

C.E.R.A.; Darbepoetin alfa; Erythropoiesis stimulating agent; Injection pain; Visual analog scale

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; INJECTION SITE PAIN; MALE; NORMAL HUMAN; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PLACEBOS; POLYETHYLENE GLYCOLS;

EID: 37749046134     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242700     Document Type: Article

References (39)

1. National Kidney Foundation Web site. Available from http://www.kidney.org [Last accessed 9 Aug 2007]
2. Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14:2919-25
3. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111
4. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-66
5. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825-30
6. Epogen® (Epoetin alfa) [US prescribing information]. Thousand Oaks, CA; Amgen Inc., 2007. Available from http://www.amgen.com/pdfs/misc/epogen_pi. pdf [Last accessed 8 Jun 2007]
7. Aranesp® (darbepoetin alfa) [US prescribing information]. Amgen Inc., 2007. Available from http://www.aranesp.com/ professional/ prescribing_information.jsp [Last accessed 8 Jun 2007]
8. Macdougall IC. C.E.R.A. (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40
9. Brandt M, Lanzendorfer M, Frische J. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006;21(Suppl 4):iv9
10. Dougherty FC, Reigner B, Jordan P, et al. A continuous erythropoietin receptor activator (C.E.R.A.) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004;15(Suppl 3):iii57
11. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5
12. Macdougall IC, Reigner B, Dougherty FC. Consistent pharmacokinetic properties of C.E.R.A (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Am J Kidney Dis 2006;47:A41
13. Macdougall IC, Walker R, Provenzano R, et al., on behalf of the ARCTOS Study Investigators. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, CA, USA
14. Canaud B, Braun J, Locatelli F. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Presented at the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; July 15-18, 2006. Glasgow, Scotland, UK [abstract SP425]
15. Sulowicz W, Locatelli F, Balla J. Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Presented at the European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) Congress; July 15-18, 2006; Glasgow, Scotland, UK [abstract SP424]
16. Klinger M, Arias M, Vargemezis, et al., on behalf of the AMICUS Study Investigators. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, CA, USA
17. Levin NW, Fishbane S, Cañedo FV, et al, on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). The Lancet 2007;370:1415-21.
18. Levin NW, Imbasciati E, Combe C, et al., on behalf of the MAXIMA Study Investigators. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender, or diabetic status. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, CA, USA
19. Sulowicz W, Locatelli F, Ryckelynck JP, et al., for the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
20. Ryckelynck J-P, Harris K, Selgas R, et al., on behalf of the PROTOS Study Investigators. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. Poster presented at The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, CA, USA
21. Brazeau GA, Cooper B, Svetic KA, et al. Current perspectives on pain upon injection of drugs. J Pharm Sci 1998;87:667-77
22. Frenken LA, van Lier HJ, Gerlag PG, et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ 1991;303:288
23. Lui SF, Leung CB, Li PK, et al. Pain after subcutaneous injection of erythropoietin. BMJ 1991;303:856
24. Granolleras C, Leskopf W, Shaldon S, et al. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294-8
25. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992;12:68-72
26. Stevens JM, Auer J, Strong CA, et al. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991;6:487-94
27. Bommer J, Weinreich T, Ritz E, et al. Efficacy of subcutaneous or intravenous recombinant human erythropoietin therapy in dialysis patients. Nephrol Dial Transplant 1989;4:471 [abstract]
28. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41-4
29. Yu AW, Leung CB, Li PK, et al. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int J Artif Organs 1998;21:341-3
30. Frenken LA, van Lier HJ, Jordans JG, et al. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 1993;22:553-6
31. Frenken LA, van Lier HJ, Koene RA. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa. Nephrol Dial Transplant 1994;9:1295-8
32. Morris KP, Hughes C, Hardy SP, et al. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help? Nephrol Dial Transplant 1994;9:1299-301
33. Cummings EA, Reid GJ, Finley GA, et al. Prevalence and source of pain in pediatric inpatients. Pain 1996;68:25-31
34. Schaeffer F. Increased subcutaneous injection pain with darbepoetin alfa compared with epoetin beta in children: results of a randomized, double-blind study. Poster presented at the American Society of Nephrology (ASN) Renal Week; October 29-November 4, 2004; St. Louis, Missouri, USA
35. Geary DF, Keating LE, Vigneux A, et al. Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 2005;68:1759-65
36. Schmitt CP, Nau B, Brummer C, et al. Increased injection pain with darbepoetin alfa compared to epoetin-beta in paediatric dialysis patients. Nephrol Dial Transplant 2006;21:3520-4
37. Choukroun G, Gelu-Mantoulet S, Rouanet S, et al. Pain at the injection site: results of the first cross-over study comparing epoetin beta and darbepoetin alfa administered subcutaneously in healthy volunteers. Presented at the European Renal Association-European Dialysis and Transplantation Association (KLII ERA-EDTA) Congress; June 4-7, 2005; Istanbul, Turkey [abstract MP187]
38. SmPC Aranesp® (darbepoetin alfa). For injection. February 28, 2006. Available from http://www.emea.europa.eu/humandocs/ Humans/EPAR/aranesp/aranesp. htm [Last accessed 12 Oct 2007]
39. Machin D, Lewith GT, Wylson S. Pain measurement in randomized clinical trials. A comparison of two pain scales. Clin J Pain 1988;4:161-8